Over the 5-year follow up, the GLP-1 analog cohorts developed less events compared with DPP4i cohort: cerebral infarction (389 vs. 478, HR 0.76 [95% CI: 0.67, 0.87]; p < 0.0001), MI (399 vs. 516, HR 0.72 [95% CI: 0.63, 0.82]; p < 0.0001), DVT (147 vs. 169, HR 0.70 [95% CI: 0.57, 0.87]; p = 0.001), PE (192 vs. 201 HR 0.90 [95% CI: 0.74, 1.09]; p = 0.282). Here, GLP1R is linked to brain infarction.